SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat is gaining attention, with community members highlighting its recent launch on Phantom Wallet and potential for significant growth. The conversation revolves around 'moon' and 'rocket' references suggesting possible rapid price appreciation. Some users are pointing out potential scam risks.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending following FDA approval of their leukemia drug, Revuforj, though a boxed warning regarding potentially fatal side effects tempers initial enthusiasm. The community is debating the impact of the safety label, comparing it to competitor Kura Oncology's profile, and weighing whether the market is overreacting given the drug's efficacy and the unmet need it addresses. Some believe the dip is a buying opportunity, while others worry about potential risks and side effects.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors closely monitor the Gen AI Summit for potential catalysts, with speculation around new contracts and strategic partnerships driving community interest; analysts have increased price targets, further fueling the bullish sentiment. Discussions also focus on the company's competitive positioning in the AI data market and its potential for expansion into enterprise and government sectors. Despite some concerns about high valuation, the overall tone remains optimistic, as investors eagerly await further developments and Q3 earnings results.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

GBTC is trending as Bitcoin flirts with all-time highs, driving discussion about potential breakouts and future price targets. Community members are closely watching technical indicators and whale activity, anticipating a continued uptrend. Broader market factors, like potential shifts from gold to Bitcoin and the impact of government policies, are also being considered.

AABG Token

AABB is trending as investors discuss the potential for a share squeeze and look forward to upcoming news regarding the wallet, dividends, and a potential legal action against market manipulation. Community members express confidence in the company's progress and are accumulating shares while awaiting key catalysts. The rise in gold and silver prices is also fueling optimism for AABB's future.

Aflac, Inc. is a holding company, which engages in the provision of financial protection services. It operates through the following segments: Aflac Japan and Aflac U.S. The Aflac Japan segment offers life insurance, death benefits, and cash surrender values. The Aflac U.S. segment sells voluntary supplemental insurance products for people who already have major medical or primary insurance coverage. The company was founded by John Amos, Paul Amos and William Amos on November 17, 1955 and is headquartered in Columbus, GA.

Aflac Inc.

Aflac is trending as traders discuss potential options strategies and ROI opportunities, with particular interest in calls expiring in 2025 and 2027. Community members are weighing the stock's technical indicators, buyback program, and analyst ratings, while considering both short-term gains and long-term dividend prospects. Some investors are reacting to recent news, including updated ratings from analysts and the company's cybersecurity incident disclosure.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to increased interest in AI-driven healthcare solutions, particularly after presenting at the GITEX Global conference in Dubai. The community is focused on the stock's high short interest and potential for a short squeeze, referencing NVIDIA's investment as a positive signal. Some anticipate news or catalysts that could trigger a significant upward move.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG, a ProShares Short Dow30 ETF, is trending as traders discuss its potential for hedging against a possible market pullback, particularly with the Dow showing signs of volatility. The community highlights call options and celebrates the strong community supporting the Bitcoin-native meme coin, $DOG, with some anticipating major exchange listings and comparing it to early Dogecoin.

XDC Network is an enterprise-ready hybrid Blockchain technology company optimized for international trade and finance. The XDC Network is powered by the native coin called XDC. The XDC protocol is architected to support smart contracts, 2000TPS, 2seconds transaction time, KYC to Masternodes (Validator Nodes). The XDC Chain (XinFin Digital Contract) uses XinFin Delegated Proof of Stake (XDPoS), with the intending to create a ‘highly-scalable, secure, permission, and commercial grade’ blockchain network. XinFin mainnet token XDC and also creates an opportunity to utilize the XinFin’s real-world use-cases such as TradeFinex.org, helps small and medium businesses or institutions originate their own financial requirements in a digital, fully structured manner so that they can distribute it to the bank or non-bank funders themselves using a common distribution standard.

XinFin Network

XDC is trending as the community discusses its potential for real-world asset tokenization and adoption in trade finance, with some highlighting its regulatory alignment and institutional partnerships. Despite some frustration over price stagnation, many believe XDC is a sleeping giant poised for significant growth, particularly with upcoming catalysts and infrastructure developments. Conversations also mention potential listings on major exchanges and comparisons to other ISO 20022 compliant cryptocurrencies.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with the community debating potential price movements and the impact of broader market factors like interest rate expectations. Discussions also involve technical analysis and long-term growth prospects, with some users expressing excitement and others cautioning about potential pullbacks.  The potential for S&P 500 inclusion and crypto trading are also fueling bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key

Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.

Lightning Round: I'm a buyer of Novartis, says Cramer

CNBC's Jim Cramer answers calls from viewers and offers advice for their stock picks...

Cramer's Lightning Round: Novartis is a buy

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...

Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why 

Novartis (NVS) could produce exceptional returns because of its solid growth attributes.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Will Positive Regulatory Updates Further Boost INCY Stock?

Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

NVS
Novartis AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVS News

NVSNovartis AG